TRACON Pharmaceuticals Inc. (TCON): Market Cap jumped to 10.95M


TRACON Pharmaceuticals Inc. (NASDAQ:TCON) changes shares on Friday trading session, with a change of -0.50% or -$0.01 shares. The trading starts at $2.06 and closed at $2.02 throughout the day. The trading session low price was $1.97 and day high was $2.06 on Friday, June 19. After the session, the Healthcare sector daily volume shifted to 0.21 million while its average volume is 304.67K. In other hand, the TCON market cap reached to $10.95M. While, its current target price is $2.01 according to WSJ.

Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is up 0.50% and up 4.69% for month. Its quarterly performance was 73.28% above, while its half year performance is down -22.69%. TCON yearly performance stood at negative -69.17% and fall -14.10% for year-to-date. Current recommendation for TRACON Pharmaceuticals Inc. is 2.20.

Earnings per share or EPS is an important financial measure, which defines the profitability of a company. TCON EPS (TTM) for 12-month is -5.87. EPS for this year is 42.40%, while for the next year its value is -3.12. Its EPS Q/Q reached 67.80%. It has an EPS of -4.90% down for past five years.

Let’s take a look on the analyst recommendations on TCON for the current month and previous month. For the current month, 1 of 3 analysts recommend stock as Buy while 0 as Sell, 0 as overweight, 0 as underweight and 2 as Hold. As compared with the previous month ratings, 0 analysts participate in stock recommendation. Out of 0, 0 rated it sell, 0 rated it as Buy and 0 as Hold Ratings. On the other hand, target price ranges from $3.00-$4.00. Average target price for TCON was reached at $3.50.

The insider ownership moved to 1.20% and institutional holding shifted to 25.80%.

The company posted an EPS (TTM) of -5.87. According to the most recent quarter report on (Jun 2020), 3 analysts estimated an average EPS of -0.73, while -2.1 EPS posted a year ago period. Analyst Estimated EPS for TCON published in the report was -0.74–0.71 during the same period. Comparing with last year, the average estimated EPS was -2.1 which is lower than -0.78 which was posted for recent quarter EPS.

A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for TCON fall -31.95% for period of 200 days. SMA for 50 days was -0.82% which is showing red signal, while SMA-20 was -3.90%. The moving average value for TRACON Pharmaceuticals Inc. (TCON) is 2.4949 and 2.0361 for 200 and 50 days respectively.

Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in TCON stock. On Jun 15, PELLETIER SAUNDRA L, Director, bought 3,000 trading shares at the cost of $2.07, which valued at 6209.0. On Jun 11, PELLETIER SAUNDRA L, Director, bought 2,500 shares at the cost of $2.00, with total shares of 2,500. On May 22, THEUER CHARLES, President and CEO, bought 10,592 shares at the cost of 1.90. After this transaction, THEUER CHARLES total shares reached to 61,819 which valued at 20119.0.